Related Experiment Video
Updated: Jul 4, 2026
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Emerging antidyslipidemic drugs.
Rebecca L Pollex1, Tisha R Joy, Robert A Hegele
1University of Western Ontario, Blackburn Cardiovascular Genetics Laboratory, Robarts Research Institute, 100 Perth Drive, Room 406, London, Ontario, N6A 5K8 Canada.
Expert Opinion on Emerging Drugs
|June 10, 2008
Summary
Current and emerging antidyslipidemic drugs are reviewed. Combinations of existing medications offer practical solutions, while novel therapies require careful benefit-risk assessment and outcome studies for coronary heart disease (CHD) treatment.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Drug Development
Background:
- Many patients with high coronary heart disease (CHD) risk do not achieve target lipid levels with current medications.
- A subset of patients experiences adverse effects from existing antidyslipidemic drugs.
- There is a need for improved pharmaceutical strategies addressing both efficacy and tolerability gaps.
Purpose of the Study:
- To provide a comprehensive overview of current antidyslipidemic drugs.
- To discuss emerging pharmaceutical agents for dyslipidemia management.
- To highlight future directions in lipid-lowering therapies.
Main Methods:
- Focused review of established drugs: statins, bile acid sequestrants, fibrates, ezetimibe, and niacin.
- Identified emerging drugs through Pharmaprojects database search (Phase II/III).
- Included searches for 'hypercholesterolemia drugs', 'HDL-based therapies', and 'PCSK9 inhibition'.
Main Results:
- Combinations of existing antidyslipidemic medications are readily applicable for patient care.
- Strategies to increase HDL-C depend on understanding HDL metabolism complexity.
- Novel LDL-C lowering approaches require thorough benefit-risk evaluation.
Conclusions:
- Current treatment options include established drug classes and their combinations.
- Emerging therapies targeting HDL-C and further LDL-C reduction are under development.
- Late-phase coronary heart disease outcome studies are crucial for validating new antidyslipidemia treatments.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:24Lipid Absorption
Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:27Bioavailability Enhancement: Drug Permeability Enhancement
After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...